Table 1.
Patient characteristics
| overall | cohort A | cohort B | p-value* | |
|---|---|---|---|---|
| n = 56 | n = 28 | n = 28 | ||
| sex (m/f) | 33/23 | 18/10 | 15/13 | 0.666 |
| age (years; mean ± SD) | 66.4 ± 9.9 | 68.0 ± 8.9 | 64.8 ± 10.8 | 0.666 |
| BMI (mean ± SD) | 26.8 ± 5.2 | 25.9 ± 4.7 | 27.0 ± 5.5 | 0.705 |
| ASA (n) | 0.666 | |||
| 1 | 1 | 1 | 0 | |
| 2 | 18 | 8 | 10 | |
| 3 | 34 | 19 | 15 | |
| 4 | 1 | 1 | ||
| type of surgery (n) | 0.666 | |||
| pylorus preserving | 47 | 22 | 25 | |
| pancreatic left resection | 9 | 6 | 3 | |
| carcinoma type (n) | 0.666 | |||
| Adenocarcinoma | 48 | 23 | 25 | |
| NET | 4 | 3 | 1 | |
| IPMN carcinoma | 3 | 3 | 0 | |
| Acinar cell carcinoma | 1 | 1 | ||
| UICC stadium (n) | 0.666 | |||
| IA | 2 | 1 | 1 | |
| IB | 6 | 3 | 3 | |
| IIA | 10 | 8 | 2 | |
| IIB | 22 | 7 | 15 | |
| III | 10 | 4 | 6 | |
| IV | 4 | 4 | 0 | |
| CRM status (R0 > 1 mm/R1 ≤ 1 mm) | 32/24 | 18/10 | 14/14 | 0.666 |
| CTx received (n) | 39 | 18 | 21 | 0.666 |
| complications | 0.666 | |||
| Clavien Dindo Grade III-IV | 7 | 2 | 5 | |
| Clavien Dindo < III | 5 | 1 | 4 | |
| ICU stay (days; mean ± SD) | 6.3 ± 5.5 | 5.4 ± 2.9 | 7.2 ± 7.3 | 0.666 |
| Hospital stay (days; mean ± SD) | 23.0 ± 17.8 | 20.0 ± 8.0 | 26.4 ± 24.3 | 0.666 |
| recurrence (n) | 27 | 15 | 12 | > 0.999 |
| 30 day mortality (n) | 5 | 2 | 3 | > 0.999 |
| death during follow-up (n) | 17 | 10 | 7 | 0.666 |
NET Neuroendocrine Tumour
IPMN Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma
CRM circumferential resection margin
CTx Chemotherapy
BMI Body Mass Index
ASA American Society of Anesthesiologists Physical Status classification
UICC Union for International Cancer Control
ICU Intensive Care Unit
*corrected p-values (false discovery rate); for ordinal- or nominal-scaled data the Chi2-test or the Fisher exact test were used, for interval-scaled data, Mann–Whitney U test was used